Text Size

Healthy Volunteer Study of Sildenafil Effects Upon Vision

This study has been completed.
Sponsor:
Information provided by:
University of Cambridge
ClinicalTrials.gov Identifier:
NCT00251784
First received: November 9, 2005
Last updated: NA
Last verified: December 2003
History: No changes posted
  Purpose

Patients sometimes report subjective visual effects when taking sildenafil. Our study set out to measure these in a controlled setting. Subjects were asked to detect patterns presented on a monitor screen.


Condition Intervention Phase
Blindness
 Drug: Sildenafil
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Educational/Counseling/Training
Official Title: A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Cambridge:

Study Start Date: February 2002
Estimated Study Completion Date: June 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: male -

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00251784

Sponsors and Collaborators
University of Cambridge
Investigators
Principal Investigator: Morris J Brown, MD University of Cambridge
Study Director: John Mollon, FRS University of Cambridge
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00251784     History of Changes
Other Study ID Numbers: LREC 98/297
Study First Received: November 9, 2005
Last Updated: November 9, 2005
Health Authority: United Kingdom: National Health Service

Additional relevant MeSH terms:
Blindness
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms
Sildenafil
 Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 19, 2013